The St. Louis-based Brain Tumor Funders' Collaborative — a coalition of six private funders of brain-tumor research — has announced grants totaling $3 million in support of four multi-institutional research teams studying aspects of immunotherapy in primary brain tumors.
Research teams sponsored by the David Geffen School of Medicine at UCLA (Robert Prins, team leader), McGill University (Daniella Quail), UPMC Children's Hospital of Pittsburgh (Gary Kohanbash), and the University of California, San Francisco (Joseph Costello) will each receive $750,000 over three years. Selected from among seventy-nine applicants, the teams will examine vaccination strategies, the micro-environment for tumors, anti-tumor T-cells, and personalized immunotherapy approaches.
"Our goal is to promote the rapid translation of scientific discoveries into effective new treatments for brain cancer patients," said Susan M. Fitzpatrick, president of the James S. McDonnell Foundation, one of the six BTFC funding partners. "By working together, we can provide a higher level of support for advancing the frontiers of brain tumor research."